Actos Lawsuit: Takeda Failed to Warn About Actos Cancer
An Actos side effects lawsuit filed by Richard W. West accuses Takeda Pharmaceuticals of failing to warn Actos users about the risk of developing bladder cancer.
West filed his lawsuit — Richard W. West vs. Takeda Pharmaceuticals — on July 20, 2012 with the Circuit Court of Cook County, Illinois.
West says he developed Actos bladder cancer after taking the drug for more than 10 years. West started taking Actos in 1999. He developed bladder cancer in 2008 and stopped taking the medication, which is used to help those with Type II diabetes manage their blood sugar, in 2012.
Bladder cancer is one of several Actos side effects that have prompted plaintiffs like West to file lawsuits against Takeda. Judge William Maddux is overseeing the West case.
Actos side effects
The Food and Drug Administration (FDA) approved Actos in 1999 to help those with Type II diabetes effectively process sugar. Not long after FDA approval, several side effects came to light, including Actos heart failure and bladder cancer.
Several studies, including the 2005 PROactive clinical trial, have shown a strong link between Actos use and bladder cancer. One of the most serious side effects, cancer is far more likely to develop in patients taking Actos than in those taking comparable medication.
On June 15, 2011, the FDA released a safety announcement stating that those taking Actos for more than 12 months are 40 percent more likely to develop bladder cancer than those not taking the drug. For patients such as West, who took Actos for more than 10 years, this news is particularly damaging.
Despite evidence supporting the prevalence of the Actos cancer, Takeda continues marketing the medication as safe for use.
Bladder cancer risk prompts European Actos recall
Plaintiffs such as West accuse Takeda of failing to warn the public about serious side effects, such as Actos bladder cancer. Although the medication has not been recalled in the U.S., in 2011, an Actos recall was issued in France and Germany.
The French Public Health Insurance Office highlighted the increased risk of developing cancer in those taking the drug for more than 24 months when the Actos recall was issued.
Although a European Actos recall has been issued, the drug remains on the U.S. market.